FDA Approved: ZYDELIG — Supplemental Application (Gilead Sciences, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for ZYDELIG (idelalisib) filed by Gilead Sciences, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Follicular Lymphoma
• Marginal Zone Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• Zydelig (idelalisib)

Snippet

SUPPL AP for ZYDELIG (IDELALISIB)